According to filings with the U.S. Securities and Exchange Commission, Redona Therapeutics is raising $11,907,796.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Kazumi Shiosaki played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Redona Therapeutics
Redona Therapeutics is focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases. By targeting ncRNA modulating proteins (RMPs), we can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. Recent science has cast a new light on understanding how certain enzymes are involved in the dysregulation of RNA and DNA processing and sensing mechanisms, and therefore contribute to the development and maintenance of serious diseases. As the understanding of these processes and the role of these enzymes in health and disease continues to expand, we are poised to quickly target these enzymes and to reverse the disease process through novel and differentiated therapeutics.

To learn more about Redona Therapeutics, visit http://redonatx.com/

Contact:
Kazumi Shiosaki, President and Chief Executive Officer
617-603-6060

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.